Conduct↦Safety↦Medicinal Product Safety Reporting↦Adverse Event
What is it? Why is it important?
An Adverse Event (AE) is any untoward medical occurrence in a participant administered an Investigational Medicinal Product (IMP), but which does not necessarily have a causal relationship with the treatment.
AE is defined as:
- An unfavourable and unintended sign (e.g. abnormal laboratory finding), or
- A symptom or disease temporally associated with the use of an Investigational Medicinal Product (IMP)
In studies, the assessment of AEs is mandatory (e.g. based on the Swiss Law; Human Research Act (HRA). Still, the extent of AE documentation and reporting depends on the risk-category of the study.
As required, AE documentation and reporting start and is mandatory once the participant has signed the Informed Consent Form (ICF) until:
- Study termination (e.g. last study participant at last study visit), or
- The end of some predefined safety follow-up period (e.g. as defined in the study protocol)
What do I need to do?
- Perform AE assessments. In the event of a serious event, proceed accordingly (see SAE reporting)
- As applicable and in accordance to the study protocol, document AEs in a standardised manner (e.g. patient-file and eCRF). Include any medical care provided to participants
- Follow reporting requirements as defined in the study protocol (e.g. reporting timelines from Site-INV to SP-INV, summary of all AEs in a study report and a clinical study report at the end of the study)
During study conduct, the requirement of AE documentation depends on study risk:
- Category A (low risk): has no documentation requirements except:
- If required based on the study protocol
- The study outcome / endpoint is the safety outcome of the study
- Category B (medium risk) and Category C (high risk): must document all AEs critical to the safety evaluation
Where can I get help?
Your local Research Support Centre↧ can assist you with experienced staff regarding this topic
Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch
Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch
Bern, Department of Clinical Research (DCR), dcr.unibe.ch
Geneva, Clinical Research Center (CRC), crc.hug.ch
Lausanne, Clinical Research Center (CRC), chuv.ch
St. Gallen, Clinical Trials Unit (CTU), h-och.ch
Zürich, Clinical Trials Center (CTC), usz.ch
Documents
External Links
Swissethics - see in particular
Swissmedic - see in particular
References
CH GCP E6(R3) – see in particular guideline
- Grossary: AE definition
- 2.7 Medical Care and Safety Reporting
- 3.9 Sponsor Oversight
- 3.13 Safety Assessment and Reporting
- Appendix B.9 Assessment of safety
ICH E8(R1) – see in particular
- 6.2 Participant safety during study conduct
ICH E2A – see in particular chapter
- Chapter II Definition
Swiss Law
ClinO – see in particular article
- Art. 39 Documentation of AE